Physician profile
Sandhya Salguti
NPI 1588778625
$6,495.85
in general payments reported to CMS, 2019-2025
35 companies · $336 in 2025
The $336 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,080 · 2020: $501 · 2021: $963 · 2022: $1,241 · 2023: $1,050 · 2024: $1,325 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,711.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,656.32 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $592.94 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $471.01 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $435.77 | 2019-2025 | |
| Janssen Biotech, INC. | $362.27 | 2019-2024 | Stelara, Tremfya, Simponi Aria |
| Merck Sharp & Dohme LLC | $355.90 | 2019-2024 | Dificid, Zinplava, Zerbaxa |
| Shionogi INC | $242.61 | 2019-2020 | |
| Celgene Corporation | $218.43 | 2021-2024 | Zeposia |
| Medtronic, INC. | $202.90 | 2024-2025 | Interstim, Pillcam |
| Braintree Laboratories, INC. | $156.18 | 2019-2025 | Suflave, Sutab |
| Boston Scientific Corporation | $134.85 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $134.00 | 2022-2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $130.99 | 2021-2023 | |
| Thd America, INC. | $124.23 | 2022 | |
| Ironwood Pharmaceuticals, INC | $122.54 | 2021-2024 | Linzess |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $116.44 | 2020-2024 | |
| Ferring Pharmaceuticals INC. | $108.84 | 2019-2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $103.21 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $97.86 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $93.52 | 2022-2024 | |
| Daiichi Sankyo INC. | $77.16 | 2021-2024 | Injectafer |
| Lilly USA, LLC | $65.00 | 2024 | Omvoh |
| Ucb, INC. | $61.51 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $59.92 | 2019-2023 | Ocaliva |
| Madrigal Pharmaceuticals | $58.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $51.93 | 2020-2023 | |
| Celltrion USA INC. | $45.14 | 2024 | Vegzelma |
| Aimmune Therapeutics, INC. | $42.61 | 2023-2024 | |
| Qol Medical, LLC | $34.71 | 2021-2022 | |
| Blueprint Medicines Corporation | $31.32 | 2023 | |
| Allergan, INC. | $30.05 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.17 | 2023-2024 | Cyltezo |
| Amgen INC. | $19.14 | 2023 | Amjevita |
| Organon LLC | $18.52 | 2023 | Renflexis |
| Lexicon Pharmaceuticals, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Salguti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.